SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy
NCT05344690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180
Last updated 2024-02-07
Summary
A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.
Conditions
Interventions
- GENETIC
-
SLMAP and EPO genetic polymorphism
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Sponsors & Collaborators
-
Ain Shams University
lead OTHER
Principal Investigators
-
Lamiaa M El Wakeel, PhD · Faculty of Pharmacy, Ain Shams University
Eligibility
- Min Age
- 30 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-20
- Primary Completion
- 2023-04-30
- Completion
- 2023-06-30
Countries
- Egypt
Study Locations
More Related Trials
-
Phenotyping Diabetic Retinopathy
NCT00840541 ·Status: COMPLETED
-
Study of Natural Course Progression of Diabetic Retinopathy
NCT06269419 ·Status: RECRUITING
-
Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs
NCT04935749 ·Status: RECRUITING
-
Genetic Markers and Proliferative Diabetic Retinopathy
NCT02879422 ·Status: COMPLETED ·Phase: NA
-
Management of Diabetes Mellitus Patients With Retinopathy
NCT00828425 ·Status: COMPLETED
-
Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification
NCT07038967 ·Status: RECRUITING
-
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
NCT01168258 ·Status: TERMINATED
-
Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema
NCT07295704 ·Status: RECRUITING
-
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
NCT01496040 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A New Treatment of Retinitis Pigmentosa
NCT03998384 ·Status: UNKNOWN ·Phase: NA
-
Prophylactic PRP in Moderate NPDR
NCT05543564 ·Status: COMPLETED
-
The Diabetic Retinopathy Screening, Prevention and Control Program
NCT04240652 ·Status: RECRUITING
-
Treating Early Stage Diabetic Retinopathy
NCT05132660 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides
NCT00501878 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers of Diabetic Retinopathy Progression
NCT01607190 ·Status: COMPLETED
-
Diabetic Retinopathy and Visual Function Study
NCT00001346 ·Status: COMPLETED
-
Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy
NCT04469777 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Research on Retinal Neovascularization of Diabetic Retinopathy
NCT01229540 ·Status: TERMINATED ·Phase: NA
-
Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients
NCT04930224 ·Status: COMPLETED
-
Safety of Trypan Blue on Endothelium of Diabetic Retinopathy Patients
NCT03755752 ·Status: COMPLETED ·Phase: NA
-
Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients
NCT02099981 ·Status: COMPLETED ·Phase: PHASE1
-
Visual Function, Center Point Thickness and Macular Volume After Photocoagulation
NCT00906659 ·Status: COMPLETED
-
Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.
NCT02151695 ·Status: COMPLETED ·Phase: PHASE2
-
Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
NCT05806957 ·Status: UNKNOWN
-
Long Term Follow-Up of Diabetic Retinopathy
NCT00001395 ·Status: COMPLETED